Reactive neutralizing human anti-GP120 recombinant antibody, DNA coding the same and use thereof
AssigneesDana-Farber Cancer Insitute, New England Deaconess Hospital Corporation
InventorsJoseph G. Sodroski, Wayne A. Marasco, Marshall R. Posner, William A. Haseltine
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a recombinant human monoclonal antibody which binds to a discontinuous epitope on the HIV gp120 envelope glycoprotien, blocks the binding of gp120 to the CD4 receptor, and neutralizes a broad range of HIV isolates. The present invention also provides the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the recombinant monoclonal antibody of the present invention, and a method of screening for antibodies which block binding of envelope glycoprotein to the CD4 receptor.
Claims6
An isolated DNA segment comprising a nucleotide sequence as defined in the Sequence Listing by SEQ ID NO:1 or SEQ ID NO:3.
An isolated DNA sequence containing a promoter operably linked to the DNA sequence of SEQ ID NO:1 and SEQ ID NO:3, wherein expression of the sequence results in expression of an antibody having affinity for a HIV-1 gp120 epitope or neutralizing ability in an in vitro assay for HIV-1.
An isolated DNA segment comprising nucleotides 58-426 of SEQ ID NO:1.
An isolated DNA segment comprising nucleotides 58-387 of SEQ ID NO:3.
Dependencies are inferred from the claim text.